New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors

• Status: Recruiting
• Trial end date: 2022-07-04
• Target enrollment: 0
• Participant gender: Female

Summary

Oocyte donation is a cumbersome and demanding procedure, involving an injectable hormonal treatment for an average duration of 12 days, according to the protocols, 1 to several daily injections. The objective of this study is to show that treatments can be simplified without reducing the number of oocytes that have been punctured, by blocking the luteinizing hormone (LH) surge by using oral progesterone and by limiting the number of injections of gonadotropins using corifollitropin alpha, regardless of the start date of the pacing protocol during a natural cycle.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Intercommunal Creteil
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Desogestrel; Progestins

Criteria

Inclusion Criteria:

• Donor of oocytes having spontaneous and regular menstrual cycles, and having taken no hormonal treatment (in particular contraceptive) during the cycle preceding the donation.

• Patient with normal ovarian reserve with antral follicle count> 8,

• BMI between 18 and 32

• Regular natural menstrual cycles, and absence of hormonal treatment during the cycle preceding the donation cycle

• Major patient

• Affiliation to social security

Exclusion Criteria:

• Stage 3-4 endometriosis

• ovarian cyst> 30 mm,

• Polycystic ovary syndrome

• Patient under tutorship or curatorship